Neuroleptic-induced catalepsy as a model of Parkinson's disease I. Effect of dopaminergic agents
作者： P. J. Elliott , S. P. Close , D. M. Walsh , A. G. Hayes , A. S. Marriott
DOI: 10.1007/BF02260896
关键词:
摘要: Catalepsy was observed in the rat following intrastriatal injections of dopamine antagonists sulpiride or fluphenazine and after subcutaneous administration fluphenazine. The neuroleptic-induced catalepsy reversed by classical anti-parkinsonian agent L-DOPA agents that function through systems such as d- methamphetamine direct D2 receptor agonist quinpirole. D1 SKF 38393, D1/D2 apomorphine, were ineffective this model. These results support limited use model for screening potential compounds indicate procedure can provide valuable information concerning striatal function.
springer.com
sci-hub.se 参考文章(31)
John Hyttel, Jørn Arnt, Characterization of Dopamine D-1 and D-2 Receptors Neurobiology of Central D1-Dopamine Receptors. ,vol. 204, pp. 15- 28 ,(1986) , 10.1007/978-1-4684-5191-7_2
Abraham N. Lieberman, Menek Goldstein, Treatment of advanced Parkinson's disease with dopamine agonists Movement Disorders#R##N#Neurology. pp. 146- 165 ,(1981) , 10.1016/B978-0-407-02295-9.50014-X
S.P. Close, A.S. Marriott, Sharon Pay, Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. British Journal of Pharmacology. ,vol. 85, pp. 320- 322 ,(1985) , 10.1111/J.1476-5381.1985.TB08863.X
Richard J. Miller, Peter H. Kelly, John L. Neumeyer, Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain. European Journal of Pharmacology. ,vol. 35, pp. 77- 83 ,(1976) , 10.1016/0014-2999(76)90302-2
Werner Poewe, Birgit Kleedorfer, Michaela Wagner, Thomas Benke, Thomas Gasser, Wolfgang Oertel, SIDE-EFFECTS OF SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE The Lancet. ,vol. 333, pp. 1084- 1085 ,(1989) , 10.1016/S0140-6736(89)92487-2
A. Braun, G. Fabbrini, M. M. Mouradian, C. Serrati, P. Barone, T. N. Chase, Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. Journal of Neural Transmission. ,vol. 68, pp. 41- 50 ,(1987) , 10.1007/BF01244638
B. Costall, J.E. Olley, Cholinergic- and neuroleptic-induced catalepsy: Modification by lesions in the caudate-putamen Neuropharmacology. ,vol. 10, pp. 297- 306 ,(1971) , 10.1016/0028-3908(71)90053-0
Emanuel Meller, Shigeki Kuga, Arnold J. Friedhoff, Menek Goldstein, Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Life Sciences. ,vol. 36, pp. 1857- 1864 ,(1985) , 10.1016/0024-3205(85)90159-6
Kathy M. O'Boyle, J.L. Waddington, New substituted 1-phenyl-3-benzazepine analogues of SK&F 38393 and N-methyl-thienopyridine analogues of dihydroxynomifensine with selective affinity for the D-1 dopamine receptor in human post-mortem brain Neuropharmacology. ,vol. 26, pp. 1807- 1810 ,(1987) , 10.1016/0028-3908(87)90139-0
W.R. Klemm, Helmuth Block, D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways☆ Pharmacology, Biochemistry and Behavior. ,vol. 29, pp. 223- 229 ,(1988) , 10.1016/0091-3057(88)90149-9